Angiochem Inc   Report issue

For profit Phase 2 Phase 3
Founded: Montreal Canada (2003)
Status: Defunct (2018)

Organization Overview

First Clinical Trial
2007
NCT00539344
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Angiochem Inc

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Brain Neoplasms (Phase 3)

Breast Neoplasms (Phase 3)

Carcinoma (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Glioblastoma (Phase 2)

Glioma (Phase 2)

Lung Neoplasms (Phase 2)

Meningeal Carcinomatosis (Phase 3)

Neoplasm Metastasis (Phase 3)

Neoplasms, Second Primary (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 7